Statin therapy in heart failure: Prognostic effects and potential mechanisms

被引:43
作者
Shanes, Jeffrey G. [1 ]
Minadeo, Kira N. [1 ]
Moret, Ann [1 ]
Groner, Mordechai [1 ]
Tabaie, Sean A. [1 ]
机构
[1] Rosalind Franklin Univ Med Sci, Chicago Med Sch, Chicago, IL USA
关键词
D O I
10.1016/j.ahj.2007.05.020
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The use of statins as therapy for heart failure remains controversial. Nevertheless, many of the pleiotropic effects of statins are potentially applicable in heart failure. Although early statin trials excluded patients with heart failure because of concerns that lowering serum cholesterol could worsen an already poor, prognosis, statin treatment. has not been shown to have adverse effects on either cardiovascular events or mortality, and recent experimental and clinical studies have shown promise of benefit. Two large, ongoing trials should provide definitive evidence of the value of statin therapy for patients with heart failure. Pending those results, it is reasonable to follow current National Cholesterol Education Program guidelines in this high-risk population.
引用
收藏
页码:617 / 623
页数:7
相关论文
共 68 条
[1]
Inflammatory mediators in chronic heart failure: An overview [J].
Anker, SD ;
von Haehling, S .
HEART, 2004, 90 (04) :464-470
[2]
Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure [J].
Anker, SD ;
Egerer, KR ;
Volk, HD ;
Kox, WJ ;
PooleWilson, PA ;
Coats, AJS .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (10) :1426-&
[3]
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level [J].
Bleske, BE ;
Nicklas, JM ;
Bard, RL ;
Brook, RD ;
Gurbel, PA ;
Bliden, KP ;
Rajagopalan, S ;
Pitt, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) :338-341
[4]
Angiotensin II type 1 receptor blockers [J].
Burnier, M .
CIRCULATION, 2001, 103 (06) :904-912
[5]
Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[6]
Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy [J].
Christ, M ;
Klima, T ;
Grimm, W ;
Mueller, HH ;
Maisch, B .
EUROPEAN HEART JOURNAL, 2006, 27 (06) :691-699
[7]
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[8]
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902 [J].
Coletta, Alison P. ;
Tin, Lwin ;
Loh, P. Huan ;
Clark, Andrew L. ;
Cleland, John G. F. .
EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (05) :547-549
[9]
Cellular survival: a play in three Akts [J].
Datta, SR ;
Brunet, A ;
Greenberg, ME .
GENES & DEVELOPMENT, 1999, 13 (22) :2905-2927
[10]
Clinical significance of statin pleiotropic effects - Hypotheses versus evidence [J].
Davidson, MH .
CIRCULATION, 2005, 111 (18) :2280-2281